Annexon, Inc. (ANNX) shareholders
Close on Nov 17, 2026Market cap $709.42MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (13.90%) | 26,289,000 | 13.90% | 13G (passive) amendment | Sep 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (11.90%) | 19,518,496 | 11.90% | 13G (passive) amendment | Jun 30, 2026 |
| Jeremy C. Green Joint filing with Redmile Group, LLC (9.90%), RedCo II Offshore SPV LLC (5.50%) | 17,918,459 | 9.90% | 13G (passive) amendment | Jul 1, 2026 |
| BlackRock, Inc. | 13,128,281 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| Satter Muneer A | 10,444,134 | 7.20% | 13D (active) amendment | Nov 19, 2025 |
| State Street Corporation | 9,824,321 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (5.40%), Bvf Inc/Il (5.40%) and 1 more | 8,698,173 | 5.40% | 13G (passive) amendment | Mar 31, 2026 |
| Logos GP LLC Joint filing with Logos Global Management LP (6.00%), Logos Global Management GP LLC (6.00%) and 2 more | 6,600,000 | 6.00% | 13G (passive) | Apr 21, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANNX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 19,518,496 | 9.55% | $111.45M | +8,882,848 | 0.00% |
| BlackRock, Inc. | 13,539,744 | 6.62% | $77.31M | +2,601,235 | 0.00% |
| Redmile Group, LLC | 11,869,877 | 5.81% | $67.78M | −2,679,891 | 4.55% |
| State Street Corp | 9,824,321 | 4.81% | $56.10M | +2,905,066 | 0.00% |
| Bvf Inc/Il | 8,698,173 | 4.25% | $49.67M | – | 1.27% |
| Woodline Partners LP | 6,925,067 | 3.39% | $39.54M | +4,587,930 | 0.12% |
| Vanguard Capital Management LLC | 6,871,015 | 3.36% | $39.23M | +914,426 | 0.00% |
| Mak Capital One LLC | 5,862,180 | 2.87% | $33.47M | +1,138,137 | 4.69% |
| Goldman Sachs Group Inc | 5,825,579 | 2.85% | $33.26M | +3,672,699 | 0.00% |
| Siren, L.L.C. | 4,458,646 | 2.18% | $25.46M | +500,000 | 0.52% |
| Bain Capital Life Sciences Investors, LLC | 4,437,731 | 2.17% | $25.34M | −774,943 | 1.51% |
| Bellevue Group AG | 4,100,016 | 2.01% | $23.41M | −1,057,274 | 0.49% |
| Geode Capital Management, LLC | 4,037,193 | 1.97% | $23.06M | +659,370 | 0.00% |
| Mpm Bioimpact LLC | 3,544,354 | 1.73% | $20.24M | New | 1.23% |
| Ameriprise Financial Inc | 3,509,623 | 1.72% | $20.04M | +60,502 | 0.00% |
| Great Point Partners LLC | 3,500,000 | 1.71% | $19.99M | +1,000,000 | 3.78% |
| Adage Capital Partners Gp, L.L.C. | 3,500,000 | 1.71% | $19.99M | −800,000 | 0.03% |
| Morgan Stanley | 3,144,453 | 1.54% | $17.95M | +408,483 | 0.00% |
| Palo Alto Investors LP | 2,948,090 | 1.44% | $16.83M | – | 2.33% |
| Balyasny Asset Management L.P. | 2,830,976 | 1.38% | $16.16M | −1,055,933 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 216 | 178M | 87.2% | 31 / 81 | 79 / 27 | 43M | 20M |
| Q1 2026 | 217 | 156M | 76.3% | 66 / 86 | 50 / 15 | 44M | 18M |
| Q4 2025 | 168 | 137M | 67.0% | 41 / 72 | 30 / 14 | 44M | 9M |
| Q3 2025 | 144 | 101M | 49.6% | 33 / 51 | 36 / 17 | 17M | 15M |
| Q2 2025 | 129 | 100M | 48.9% | 19 / 50 | 35 / 37 | 10M | 10M |
| Q1 2025 | 147 | 100M | 48.8% | 25 / 56 | 39 / 28 | 13M | 15M |
| Q4 2024 | 152 | 112M | 54.9% | 29 / 60 | 38 / 18 | 17M | 16M |
| Q3 2024 | 142 | 112M | 54.8% | 22 / 57 | 38 / 18 | 19M | 13M |
| Q2 2024 | 140 | 113M | 55.1% | 39 / 53 | 34 / 26 | 30M | 15M |
| Q1 2024 | 127 | 98M | 47.8% | 39 / 42 | 27 / 11 | 26M | 9M |
| Q4 2023 | 99 | 81M | 39.6% | 20 / 38 | 26 / 13 | 32M | 4M |
| Q3 2023 | 93 | 54M | 26.2% | 14 / 30 | 28 / 15 | 8M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
184 funds held ANNX in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ANNX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 6,233,855 | 3.05% | $35.60M | 0.33% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 5,082,296 | 2.49% | $27.55M | 0.52% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 4,970,636 | 2.43% | $28.38M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,062,168 | 1.99% | $23.19M | 0.03% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 2,067,700 | 1.01% | $10.53M | 0.14% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 1,787,580 | 0.87% | $9.11M | 0.10% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,754,999 | 0.86% | $10.02M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,696,340 | 0.83% | $8.64M | 0.03% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,661,500 | 0.81% | $8.47M | 0.38% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,430,050 | 0.70% | $8.17M | 0.05% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund | 1,390,319 | 0.68% | $7.08M | 0.28% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,200,000 | 0.59% | $6.50M | 0.11% | May 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 1,187,100 | 0.58% | $6.05M | 0.13% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,009,399 | 0.49% | $5.76M | 0.06% | Jun 30, 2026 |
| Select Pharmaceuticals Portfolio | 1,003,800 | 0.49% | $5.44M | 0.36% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Douglas Love | PRESIDENT AND CEO, Director | 390,476 | 0.19% | Sep 25, 2026 |
| Ted Yednock | EVP & CHIEF INNOVATION OFFICER | 184,807 | 0.09% | Jun 15, 2026 |
| Jamie Dananberg | CHIEF MEDICAL OFFICER | 123,582 | 0.06% | Mar 4, 2026 |
| Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | 170,700 | 0.08% | Mar 4, 2026 |
| Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | 182,625 | 0.09% | Mar 4, 2026 |
| Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | 180,093 | 0.09% | Mar 4, 2026 |
| Mark S. Blumenkranz | Director | – | – | Aug 12, 2026 |
| William A. Jones Jr | Director | – | – | Jun 15, 2026 |
| Jung Choi | Director | 33,000 | 0.02% | Jun 15, 2026 |
| William H. Carson | Director | 78,405 | 0.04% | Jun 15, 2026 |
| William D. Waddill | Director | – | – | Jun 15, 2026 |
| Bettina M. Cockroft | Director | – | – | Jun 15, 2026 |
| Muneer A. Satter | Director | 10,342,134 | 5.06% | Jun 15, 2026 |
| Thomas G. Wiggans | Director | – | – | Jun 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Douglas Love PRESIDENT AND CEO, Director | Sep 24, 2026 | Buy | +26,065 | $3.83 | $99.83K | 390,476 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Jun 11, 2026 | Option exercise | +30,646 | $1.85 | $56.70K | 184,807 |
| Muneer A. Satter Director | May 28, 2026 | Buy | +613,497 | $5.41 | $3.32M | 10,342,134 |
| William H. Carson Director | May 11, 2026 | Buy | +8,000 | $5.78 | $46.24K | 78,405 |
| William H. Carson Director | Apr 10, 2026 | Buy | +8,000 | $6.20 | $49.60K | 70,405 |
| William H. Carson Director | Mar 10, 2026 | Buy | +8,000 | $5.67 | $45.36K | 62,405 |
| Michael Overdorf EVP & CHIEF BUSINESS OFFICER | Mar 2, 2026 | Sale | −4,339 | $5.42 | $23.52K | 182,625 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Mar 2, 2026 | Sale | −5,566 | $5.42 | $30.17K | 154,161 |
| Jennifer Lew EVP & CHIEF FINANCIAL OFFICER | Mar 2, 2026 | Sale | −5,565 | $5.42 | $30.16K | 170,700 |
| Dean Richard Artis EVP & CHIEF SCIENTIFIC OFFICER | Mar 2, 2026 | Sale | −5,894 | $5.43 | $32.00K | 180,093 |
| Jamie Dananberg CHIEF MEDICAL OFFICER | Mar 2, 2026 | Sale | −5,820 | $5.43 | $31.60K | 123,582 |
| Michael Overdorf EVP & CHIEF BUSINESS OFFICER | Feb 19, 2026 | Award | +62,500 | – | – | 186,964 |
| Jennifer Lew EVP & CHIEF FINANCIAL OFFICER | Feb 19, 2026 | Award | +62,500 | – | – | 176,265 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Feb 19, 2026 | Award | +62,500 | – | – | 159,727 |
| Dean Richard Artis EVP & CHIEF SCIENTIFIC OFFICER | Feb 19, 2026 | Award | +62,500 | – | – | 185,987 |
| Jamie Dananberg CHIEF MEDICAL OFFICER | Feb 19, 2026 | Award | +56,250 | – | – | 129,402 |
| Dean Richard Artis EVP & CHIEF SCIENTIFIC OFFICER | Feb 18, 2026 | Sale | −5,290 | $5.10 | $26.98K | 123,487 |
| Jennifer Lew EVP & CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Sale | −7,851 | $5.11 | $40.12K | 113,765 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Feb 18, 2026 | Sale | −7,857 | $5.11 | $40.15K | 97,227 |
| Michael Overdorf EVP & CHIEF BUSINESS OFFICER | Feb 18, 2026 | Sale | −6,225 | $5.10 | $31.75K | 124,464 |
| Jamie Dananberg CHIEF MEDICAL OFFICER | Feb 18, 2026 | Sale | −5,290 | $5.10 | $26.98K | 73,152 |
| William H. Carson Director | Dec 30, 2025 | Buy | +4,115 | $5.02 | $20.66K | 54,405 |
| Jung Choi Director | Dec 1, 2025 | Buy | +33,000 | $4.19 | $138.27K | 33,000 |
| William H. Carson Director | Dec 1, 2025 | Buy | +4,115 | $4.47 | $18.39K | 50,290 |
| Muneer A. Satter Director | Nov 21, 2025 | Buy | +422,613 | $4.28 | $1.81M | 9,728,637 |
| Muneer A. Satter Director | Nov 20, 2025 | Buy | +400,000 | $4.48 | $1.79M | 9,306,024 |
| Muneer A. Satter Director | Nov 19, 2025 | Buy | +500,000 | $3.94 | $1.97M | 8,906,024 |
| Muneer A. Satter Director | Nov 18, 2025 | Buy | +500,000 | $3.18 | $1.59M | 8,406,024 |
| Muneer A. Satter Director | Nov 17, 2025 | Buy | +500,000 | $2.99 | $1.50M | 7,906,024 |
| William H. Carson Director | Oct 30, 2025 | Buy | +4,115 | $3.17 | $13.04K | 46,175 |
| William H. Carson Director | Sep 30, 2025 | Buy | +4,115 | $3.05 | $12.55K | 42,060 |
| William H. Carson Director | Sep 2, 2025 | Buy | +4,115 | $2.09 | $8.60K | 37,945 |
| William H. Carson Director | Jul 30, 2025 | Buy | +4,115 | $2.43 | $10.00K | 33,830 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Jul 14, 2025 | Sale | −1,116 | $2.58 | $2.88K | 105,084 |
| Jennifer Lew EVP & CHIEF FINANCIAL OFFICER | Jul 14, 2025 | Sale | −1,117 | $2.58 | $2.88K | 121,616 |
| Michael Overdorf EVP & CHIEF BUSINESS OFFICER | Jul 14, 2025 | Sale | −853 | $2.61 | $2.23K | 130,689 |
| William H. Carson Director | Jun 30, 2025 | Buy | +4,115 | $2.46 | $10.12K | 29,715 |
| Jamie Dananberg CHIEF MEDICAL OFFICER | Feb 18, 2025 | Sale | −5,521 | $2.96 | $16.34K | 33,479 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Feb 18, 2025 | Sale | −8,345 | $2.91 | $24.28K | 61,237 |
| Michael Overdorf EVP & CHIEF BUSINESS OFFICER | Feb 18, 2025 | Sale | −6,618 | $2.95 | $19.52K | 86,579 |
| Dean Richard Artis EVP & CHIEF SCIENTIFIC OFFICER | Feb 18, 2025 | Sale | −5,515 | $2.97 | $16.38K | 83,814 |
| Jennifer Lew EVP & CHIEF FINANCIAL OFFICER | Feb 18, 2025 | Sale | −6,912 | $2.92 | $20.18K | 77,770 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Feb 13, 2025 | Sale | −1,783 | $2.99 | $5.33K | 69,582 |
| Douglas Love PRESIDENT AND CEO, Director | Feb 13, 2025 | Sale | −5,021 | $2.95 | $14.81K | 351,554 |
| Michael Overdorf EVP & CHIEF BUSINESS OFFICER | Feb 13, 2025 | Sale | −1,425 | $2.99 | $4.26K | 93,197 |
| Jennifer Lew EVP & CHIEF FINANCIAL OFFICER | Feb 13, 2025 | Sale | −1,786 | $2.98 | $5.32K | 84,682 |
| Douglas Love PRESIDENT AND CEO, Director | Jan 6, 2025 | Option exercise | +37,994 | $1.41 | $53.57K | 356,575 |
| William H. Carson Director | Dec 2, 2024 | Buy | +3,200 | $5.33 | $17.06K | 25,600 |
| Douglas Love PRESIDENT AND CEO, Director | Oct 30, 2024 | Option exercise | +36,050 | $1.85 | $66.69K | 310,570 |
| Douglas Love PRESIDENT AND CEO, Director | Oct 30, 2024 | Option exercise | +78,399 | $1.85 | $145.04K | 274,520 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Oct 15, 2024 | Sale(10b5-1 plan) | −5,408 | $7.41 | $40.07K | 71,365 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Oct 15, 2024 | Option exercise | +5,408 | $1.85 | $10.00K | 76,773 |
| William H. Carson Director | Oct 1, 2024 | Buy | +3,200 | $5.97 | $19.10K | 22,400 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Sep 19, 2024 | Sale(10b5-1 plan) | −4,500 | $7.10 | $31.95K | 0 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Sep 12, 2024 | Sale(10b5-1 plan) | −5,500 | $6.16 | $33.88K | 4,500 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Sep 5, 2024 | Sale(10b5-1 plan) | −5,500 | $5.64 | $31.02K | 10,000 |
| William H. Carson Director | Sep 3, 2024 | Buy | +3,200 | $5.48 | $17.54K | 19,200 |
| Ted Yednock EVP & CHIEF INNOVATION OFFICER | Aug 29, 2024 | Sale(10b5-1 plan) | −5,500 | $5.95 | $32.73K | 15,500 |
| William H. Carson Director | Aug 1, 2024 | Buy | +3,200 | $6.24 | $19.97K | 16,000 |
| Jennifer Lew EVP & CHIEF FINANCIAL OFFICER | Jul 15, 2024 | Sale | −1,104 | $6.03 | $6.66K | 86,468 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Annexon's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,715 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Thomas G. Wiggans Former Director | Aug 13, 2026 | 2,000 | $10.60K | Aug 13, 2026 | Stock Option Exercise |
| Thomas G. Wiggans Former Director | Jul 15, 2026 | 2,000 | $12.63K | Jul 15, 2026 | Stock Option Exercise |
| Thomas G. Wiggans Former Director | Jul 14, 2026 | 1,000 | $5.61K | Jul 14, 2026 | Stock Option Exercise |
| Ted Yednock Officer | Mar 2, 2026 | 5,566 | $30.18K | Mar 2, 2026 | Restricted Stock Vesting |
| Dean Richard Artis Officer | Mar 2, 2026 | 5,894 | $31.98K | Mar 2, 2026 | Restricted Stock Vesting |
| Michael Overdorf Officer | Mar 2, 2026 | 4,339 | $23.53K | Mar 2, 2026 | Restricted Stock Vesting |
| Jamie Dananberg Officer | Mar 2, 2026 | 5,820 | $31.58K | Mar 2, 2026 | Restricted Stock Vesting |
| Jennifer Lew Officer | Mar 2, 2026 | 5,565 | $30.18K | Mar 2, 2026 | Restricted Stock Vesting |
| Jennifer Lew Officer | Feb 18, 2026 | 7,851 | $40.12K | Feb 18, 2026 | Restricted Stock Vesting |
| Dean Richard Artis Officer | Feb 18, 2026 | 5,290 | $26.99K | Feb 18, 2026 | Restricted Stock Vesting |
| Ted Yednock Officer | Feb 18, 2026 | 7,857 | $40.12K | Feb 18, 2026 | Restricted Stock Vesting |
| Michael Overdorf Officer | Feb 18, 2026 | 6,225 | $31.76K | Feb 18, 2026 | Restricted Stock Vesting |
| Jamie Dananberg Officer | Feb 18, 2026 | 5,290 | $26.99K | Feb 18, 2026 | Restricted Stock Vesting |
| Ted Yednock Officer | Jul 14, 2025 | 1,116 | $2.88K | Jul 14, 2025 | Restricted Stock Vesting |
| Michael Overdorf Officer | Jul 14, 2025 | 853 | $2.23K | Jul 14, 2025 | Restricted Stock Vesting |
See a number that looks wrong?